The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).
Ursula Matulonis
No relevant relationships to disclose
Gerburg M. Wulf
No relevant relationships to disclose
Michael J. Birrer
No relevant relationships to disclose
Shannon Neville Westin
No relevant relationships to disclose
Philippa Quy
No relevant relationships to disclose
Katherine M. Bell-McGuinn
No relevant relationships to disclose
Brian Lasonde
No relevant relationships to disclose
Christin Whalen
No relevant relationships to disclose
Carol Aghajanian
No relevant relationships to disclose
David B. Solit
No relevant relationships to disclose
Gordon B. Mills
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
Lewis Cantley
No relevant relationships to disclose
Eric P. Winer
No relevant relationships to disclose